Hacer Demir
A5004225132- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Nutrition and Health in Aging
- Peptidase Inhibition and Analysis
- Cancer Risks and Factors
- Metastasis and carcinoma case studies
- Renal and related cancers
- Lung Cancer Research Studies
- Endometrial and Cervical Cancer Treatments
Universidad CES
2020-2025
Afyonkarahisar Sağlık Bilimleri Üniversitesi
2019-2025
Afyon Kocatepe University
2016-2025
Kayseri Eğitim ve Araştırma Hastanesi
2018-2025
Sağlık Bilimleri Üniversitesi
2018-2024
Marmara University
2016-2023
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi
2009-2023
Izmir University
2023
University of Health Science
2023
University of Health Sciences Antigua
2023
There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which oncologists prefer patients with disease progression under CDKi. In addition, we show the effectiveness of systemic treatments CDKi and whether there a survival difference between hormonal (monotherapy vs. mTOR-based).A total 609 from 53 centers were included study....
Despite numerous studies on second-line therapies in metastatic pancreatic cancer, there is no randomized study evaluating the efficacy of gemcitabine plus nab-paclitaxel as a treatment. This aims to examine therapy. In this retrospective study, total 218 patients from 23 centers were included. The primary endpoint was progression-free survival (PFS), secondary endpoints included overall (OS), treatment based ECOG performance status (PS), and tumor marker (CEA, CA 19 - 9) levels. with...
To evaluate the prognostic role of pan immune-inflammation value (PIV) in young breast cancer patients.Descriptive study.Department Medical Oncology, Afyon University Health Sciences, School Medicine Hospital, Turkey, between January 2010 and December 2020.Patients who were under age 40 years at time diagnosis included. Patients' characteristics disease parameters recorded. PIV was calculated according to (neutrophil x platelet monocyte/lymphocyte, i.e. NxPxM/L) formula. Since a cut-off with...
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase as the first-line standard-of-care for patients hormone receptor-positive, HER2-negative metastatic breast cancer.
Abstract Purpose This study aims to compare the clinicopathological and prognostic features of women aged 40 years younger 65 older with breast cancer. Methods Between January 2011 December 2021, 136 female cases 223 over were identified among all (1395 cases) registered as cancer in file archives Afyonkarahisar Health Sciences University Faculty Medicine, Department Medical Oncology for study. A Chi-square (× 2) test was used categorical variables, an independent sample t-test continuous...
OBJECTIVE: We aimed to compare tru-cut biopsy with laparoscopy in the diagnosis of high-grade serous ovarian cancer (HGSC) our clinic. MATERIAL AND METHODS: Our retrospective study included patients who underwent surgery for HGSC between January 2013 and December 2023. Patients pathologically confirmed (FIGO 2018) stage III or IV neoadjuvant chemotherapy (NACT) interval debulking (IDS) were performed. Exclusion criteria I II did not receive NACT. Additionally, non-high-grade...
708 Background: This study evaluates the real-world efficacy and safety of avelumab maintenance therapy in metastatic urothelial carcinoma (mUC) patients who have not progressed following first-line platinum chemotherapy, using data from EAP. Methods: The primary endpoint was overall survival (OS), progression-free (PFS) secondary endpoints included safety. PFS OS were estimated by Kaplan-Meier method. Results: One hundred seventeen received at least one cycle Avelumab. median number...
In recent years, significant success has been achieved in the treatment of metastatic melanoma with use immune checkpoint inhibitors (ICIs), and it resulted a remarkable increase patient survival. However, there are only few studies reflecting daily practice outside clinical trials. The present study aimed to evaluate effectiveness safety ICI therapy Turkish patients melanoma, including those poor prognostic factors such as advanced age brain metastasis. A retrospective analysis was...
Background and Objectives: Although breast cancer is the most common type of among women, bilateral (BBC) remains exceedingly rare. BBC can present as either synchronous (SBBC) or metachronous (MBBC) disease. Data regarding clinical characteristics are limited. In this study, we aimed to share our multicenter, retrospective experience on clinicopathological demographic features SBBC MBBC, their survival outcomes, factors influencing survival, in light current knowledge. Material Method: A...
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is MONALEESA-7 study, and data palbociclib limited. Data are also limited regarding whose dose was reduced due to neutropenia, most common side effect inhibitors. In our we aimed evaluate ribociclib reduction neutropenia progression-free survival. Our a multicenter, retrospective factors affecting survival...
Background/aim: The aim of this study was to investigate neuroendocrine tumors (NETs) detected in appendectomy specimens and the incidence clinicopathologic characteristics these our center. Materials methods: A total 13,863 patients were evaluated retrospectively. All underwent operation Kayseri Training Research Hospital had a histopathological examination at Pathology Clinic between January 2007 March 2017. Age, sex, preoperative clinical findings, procedure, results cases reported be NET...
The aim of this study is to evaluate the efficacy and toxicity trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) different lines treatment.Retrospective analysis T-DM1 results human epidermal growth factor receptor 2 (Her2) positive 414 mBC from 31 centers Turkey.Except 2, all were female a median age 47. had been used as second-line therapy 37.7% number cycles was 9. Progression-free survival (PFS) overall (OS) times according line treatment. OS found 43, 41, 46, 23...
Aim:The rapid development of the drug industry led to a great spectrum medical treatment, especially in oncology practice.The prescribed alternations increased three times United States.Also, numbers shortages, which doubled during this period era.In study, we try evaluate clinics' supply last year eyes practitioners Methods: We conducted an online questionnaire via Google Forms on shortages are faced by oncologists Turkey.Our study is cross-sectional study.The SPSS 25 software was used for...
Background Breast cancer is the most common in women. Body composition and inflammatory markers are increasingly important for predicting prognosis. The Cancer Cachexia Index (CXI) modified Glasgow Prognostic Score (GPS) two new evaluating prognosis cancer. In this study, we evaluated utility of CXI GPS young patients with breast Methods Eighty diagnosed between 2012 2023 were included study. following information was recorded: patient features, pathological subtype, estrogen receptor human...
Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in general population that is not limited by selection criteria clinical studies. The aim this study was to evaluate palbociclib or ribociclib plus fulvestrant hormone receptor-positive human epidermal factor 2-negative metastatic breast cancer (HR+/HER2-MBC). We conducted a multicenter, retrospective cohort included 522 patients with HR+/HER2-MBC treated combination fulvestrant....
The metastatic pattern of non-small cell lung cancer (NSCLC) has been described in several studies. Frequent sites are lung, liver, bone, surrenal, and brain. Hypotheses were speculated to explain the tendency specific sites. Over-expression EGFR alters biology tumoral behavior. mutations mainly occur exon 19, 21and could lead way through tumor growth metastasis. We try elucidate relationship between mutation pattern. In this retrospective nested case-control study, one hundred five patients...
The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and determine the patient group which these treatments more effective neuroendocrine tumors (NETs) a Ki-67 index 20% or less. Patients who received SSA CTx had unresectable locally advanced metastatic NETs less retrospectively selected from 13 centers Turkish database between 2000 2015. One hundred sixty-five patients enrolled. median age...